Intravitreal Anti-VEGF Therapy Blocks Inflammatory Cell Infiltration and Re-Entry into the Circulation in Retinal Angiogenesis
Intravitreal Anti-VEGF Therapy Blocks Inflammatory Cell Infiltration and Re-Entry into the Circulation in Retinal Angiogenesis
复制标题
DOI：
10.1167/iovs.11-9119
复制
发表时间：
2012-06-01
影响因子：
4.4
通讯作者：
Ishibashi, Tatsuro
中科院分区：
文献类型：
--
作者：
Nakao, Shintaro;Arima, Mitsuru;Ishibashi, Tatsuro
目的。抗vegf - a抗体（Ab）（例如，贝伐单抗，雷尼单抗）被广泛用于治疗视网膜血管生成和水肿。本研究的目的是评估玻璃体内注射抗vegf Ab是否调节视网膜血管生成中的炎症细胞。为了研究玻璃体内注射贝伐单抗是否会影响增生性糖尿病视网膜病变（PDR）患者的膜中炎症细胞的数量，在有或没有贝伐单抗预处理的玻璃体切割手术中，使用手术获得的膜进行CD45 Ab（泛白细胞标记物）免疫组织化学染色。为了检查抗vegf - a Ab是否影响视网膜血管生成过程中进出血管的白细胞，作者在氧诱导视网膜病变（OIR）小鼠模型中进行了他们的新白细胞迁移试验和CD45免疫染色。作者的新成像方法显示，玻璃体内注射抗vegf - a Ab可阻断白细胞浸润和血管生成。在影响血管生成区之前，注射Ab抑制白细胞迁移。CD45染色显示抗vegf - a Ab注射组与对照组血管新生视网膜及人PDR膜白细胞数量无显著差异。此外，VEGF-A抑制也影响从视网膜流出的白细胞。玻璃体内注射抗vegf - a抗体可抑制视网膜白细胞运输，提示抗vegf - a治疗可作为视网膜炎症的一种治疗方法。（Invest Ophthalmol Vis Sci. 2012;53:43 323-4328） DOI:10.1167/iovs.11-9119
PURPOSE. Anti-VEGF-A antibody (Ab) (e. g., bevacizumab, ranibizumab) is widely used as a treatment against retinal angiogenesis and edema. The purpose of this study was to evaluate whether intravitreal anti-VEGF Ab injection modulates inflammatory cells in retinal angiogenesis.METHODS. To investigate whether intravitreal bevacizumab injections affect the number of inflammatory cells in proliferative diabetic retinopathy (PDR) membranes in patients, immunohistochemical staining with CD45 Ab (pan-leukocyte marker) was performed using the surgically obtained membranes in pars plana vitrectomy with or without pretreatment with bevacizumab. To check whether anti-VEGF-A Ab affects leukocytes going in and out of blood vessels during retinal angiogenesis, the authors performed their novel leukocyte transmigration assay and CD45 immunostaining in a mouse model of oxygen-induced retinopathy (OIR).RESULTS. The authors' new imaging approach revealed that intravitreal injection of anti-VEGF-A Ab blocks leukocyte infiltration as well as angiogenesis. The Ab injection inhibited leukocyte transmigration before affecting the angiogenenic area. CD45 staining showed no significant difference in the leukocyte number in the angiogenic retina or the human PDR membranes between the anti-VEGF-A Ab injected group and the control group. Furthermore, VEGF-A inhibition also affected leukocytes going out from the retina.CONCLUSIONS. Intravitreal injection of anti-VEGF-A Ab could inhibit leukocyte trafficking in the retina, suggesting that anti-VEGF-A therapy could serve as a treatment in retinal inflammation. (Invest Ophthalmol Vis Sci. 2012;53:4323-4328) DOI:10.1167/iovs.11-9119